COSCIENS Biopharma Inc. (TSX:CSCI)
Canada
· Delayed Price · Currency is CAD 4.450
+0.110 (2.53%)
Apr 24, 2025, 4:00 PM EDT
COSCIENS Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -15.31 | -3.49 | 3.45 | -8.37 | -5.12 | Upgrade
|
| Depreciation & Amortization | 1.61 | 1.44 | 1.47 | 0.15 | 0.23 | Upgrade
|
| Other Amortization | - | - | - | - | 0.73 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0 | -0 | Upgrade
|
| Asset Writedown & Restructuring Costs | 4.26 | - | - | - | -0.52 | Upgrade
|
| Stock-Based Compensation | 0.46 | 0.19 | 0.07 | 0.31 | 0.06 | Upgrade
|
| Other Operating Activities | -3.07 | -0.79 | 1.18 | -3.17 | -1.91 | Upgrade
|
| Change in Accounts Receivable | -1.68 | 1.86 | -0.61 | 0.12 | -1.02 | Upgrade
|
| Change in Inventory | 1.11 | -1.16 | -1.09 | -0.06 | 1.18 | Upgrade
|
| Change in Accounts Payable | -0.82 | -0.42 | 0.81 | 0.63 | 0.05 | Upgrade
|
| Change in Unearned Revenue | 0.22 | - | - | 3.01 | 3.03 | Upgrade
|
| Change in Income Taxes | - | - | - | -0.11 | 0.4 | Upgrade
|
| Change in Other Net Operating Assets | -0.59 | -0.13 | 0.02 | -1.1 | -1.23 | Upgrade
|
| Operating Cash Flow | -14.57 | -2.58 | 5.23 | -8.58 | -4.13 | Upgrade
|
| Capital Expenditures | -1.16 | -0.72 | -0.3 | -0.03 | - | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0 | 0.01 | Upgrade
|
| Cash Acquisitions | 26.04 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | -0.61 | - | Upgrade
|
| Other Investing Activities | 0.21 | -0.01 | - | -0.02 | 0.05 | Upgrade
|
| Investing Cash Flow | 25.08 | -0.73 | -0.3 | -0.66 | 0.06 | Upgrade
|
| Long-Term Debt Repaid | -0.42 | -0.37 | -0.33 | -0.13 | -0.27 | Upgrade
|
| Net Debt Issued (Repaid) | -0.42 | -0.37 | -0.33 | -0.13 | -0.27 | Upgrade
|
| Issuance of Common Stock | - | 0.01 | 0.06 | 54.29 | 23.5 | Upgrade
|
| Other Financing Activities | -0.17 | - | - | -3.12 | -2.77 | Upgrade
|
| Financing Cash Flow | -0.59 | -0.36 | -0.27 | 51.04 | 20.47 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.21 | 0.16 | -0.63 | -0.77 | 0.04 | Upgrade
|
| Net Cash Flow | 9.72 | -3.51 | 4.03 | 41.03 | 16.43 | Upgrade
|
| Free Cash Flow | -15.73 | -3.3 | 4.93 | -8.61 | -4.13 | Upgrade
|
| Free Cash Flow Margin | -164.07% | -46.26% | 33.80% | -163.71% | -113.06% | Upgrade
|
| Free Cash Flow Per Share | -6.09 | -1.79 | 2.66 | -7.49 | -10.05 | Upgrade
|
| Cash Income Tax Paid | - | - | - | 1.61 | 1.45 | Upgrade
|
| Levered Free Cash Flow | -2.44 | -7.7 | 3.78 | -4.75 | -3.35 | Upgrade
|
| Unlevered Free Cash Flow | -2.36 | -7.61 | 3.87 | -4.75 | -3.35 | Upgrade
|
| Change in Net Working Capital | -2.94 | 5.63 | 0.06 | -0.85 | 0.67 | Upgrade
|
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.